Skip to content

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
211 items

Retinal photoreceptors use dual pathways to tell brain ‘I’ve seen the light!’

Neuroscientists at Johns Hopkins Medicine have shown that intrinsically-photosensitive retinal ganglion cells use two different pathways at the same time to transmit electrical “vision” signals to the brain.
Scientist examines scientific images on a screen in a dark room.

Retinal imaging and genetics data used to predict future disease risk

Researchers combined retinal imaging, genetics and big data to estimate how likely a person is to develop eye and systemic diseases in the future.
Pipet

New technique enhances quality control of lab-grown cells for AMD treatment

NEI researchers improved a crucial step in the production of retinal pigment epithelium (RPE), a tissue they grow in the lab from patient blood cells and are testing in a clinical trial as treatment for AMD.

NEI posts executive summary of workshop on extracellular vesicles

The September 14 workshop brought together multidisciplinary experts in extracellular vesicles – cell-secreted nanoparticles that mediate cell-cell communication.

Study identifies "visual system" protein for circadian rhythm stability

Scientists have identified a protein in the visual system of mice that appears to be key for stabilizing the body’s circadian rhythms by buffering the brain’s response to light.
Illustration of retinal cell types, including midget cells.

Cell types in the eye have ancient evolutionary origins

In a comparative analysis across animals of the many cell types in the retina, researchers concluded that most cell types have an ancient evolutionary history.

Story of discovery: NEI-funded research paves way for new dry AMD drugs

This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD).
Emily Chew

Emily Chew named NIH distinguished investigator

A longstanding member of the NEI/NIH community, Emily, Chew, M.D., has been promoted to the title of NIH Distinguished Investigator for her tireless and prolific work as a care provider and clinical trialist.
Baranov and colleague talk in the laboratory.

Mass Eye and Ear researchers develop potential glaucoma treatment strategy to guide stem cells to the retina

A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.

Innovative research unveils potential breakthrough in diabetic retinopathy treatment

NEI-funded investigators at Washington University in St. Louis discovered a potential new treatment approach to diabetic retinopathy, one of the most common causes of vision loss in the U.S.